JENNIFER HOWITT ANOLIK

Summary

Affiliation: University of Rochester
Country: USA

Publications

  1. ncbi request reprint B cell biology and dysfunction in SLE
    Jennifer H Anolik
    University of Rochester School of Medicine, Rochester, NY 14642, USA
    Bull NYU Hosp Jt Dis 65:182-6. 2007
  2. ncbi request reprint Cutting edge: anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networks
    Jennifer H Anolik
    Department of Medicine, Division of Allergy, Immunology, and Rheumatology, University of Rochester, NY 14642, USA
    J Immunol 180:688-92. 2008
  3. doi request reprint B cell biology: implications for treatment of systemic lupus erythematosus
    J H Anolik
    Department of Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA
    Lupus 22:342-9. 2013
  4. pmc Treatment targets in systemic lupus erythematosus: biology and clinical perspective
    Valentin Marian
    Department of Medicine, Division of Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, NY 14642, USA
    Arthritis Res Ther 14:S3. 2012
  5. pmc Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor
    James J Kobie
    Division of Allergy, Immunology and Rheumatology, University of Rochester Medical Center, 601 Elmwood Avenue, Box 695, Rochester, NY 14642, USA
    Arthritis Res Ther 13:R209. 2011
  6. ncbi request reprint New treatments for SLE: cell-depleting and anti-cytokine therapies
    Jennifer H Anolik
    Allergy, Immunology, Rheumatology Unit, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    Best Pract Res Clin Rheumatol 19:859-78. 2005
  7. ncbi request reprint B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny
    Jennifer H Anolik
    Department of Medicine, Division of Clinical Immunology and Rheumatology, James P Wilmot Cancer Center, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    Clin Immunol 122:139-45. 2007
  8. ncbi request reprint Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus
    Jennifer H Anolik
    University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Rochester, NY 14642, USA
    Arthritis Rheum 50:3580-90. 2004
  9. ncbi request reprint Down-regulation of CD20 on B cells upon CD40 activation
    Jennifer Anolik
    Department of Medicine, University of Rochester School of Medicine, Rochester 14642, USA
    Eur J Immunol 33:2398-409. 2003
  10. ncbi request reprint B cell depletion therapy in systemic lupus erythematosus
    Jennifer Anolik
    Department of Medicine Immunology and Rheumatology, University of Rochester School of Medicine, 601 Elmwood Avenue, Box 695, Rochester, NY 14642, USA
    Curr Rheumatol Rep 5:350-6. 2003

Research Grants

  1. B-Cell Tolerance Mechanisms in Human SLE
    JENNIFER HOWITT ANOLIK; Fiscal Year: 2010
  2. B-Cell Tolerance Mechanisms in Human SLE
    Jennifer Anolik; Fiscal Year: 2009
  3. B cell functional and signaling abnormalities in SLE
    Jennifer Anolik; Fiscal Year: 2006
  4. B-Cell Tolerance Mechanisms in Human SLE
    Jennifer Anolik; Fiscal Year: 2009

Collaborators

Detail Information

Publications31

  1. ncbi request reprint B cell biology and dysfunction in SLE
    Jennifer H Anolik
    University of Rochester School of Medicine, Rochester, NY 14642, USA
    Bull NYU Hosp Jt Dis 65:182-6. 2007
    ..Given the large body of evidence implicating abnormalities in the B cell compartment in SLE,there has been a recent therapeutic focus on developing interventions that target the B cell compartment by multiple mechanisms...
  2. ncbi request reprint Cutting edge: anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networks
    Jennifer H Anolik
    Department of Medicine, Division of Allergy, Immunology, and Rheumatology, University of Rochester, NY 14642, USA
    J Immunol 180:688-92. 2008
    ..This study provides initial evidence in humans to support the notion that anti-TNF treatment disrupts GC reactions at least in part via effects on follicular dendritic cells...
  3. doi request reprint B cell biology: implications for treatment of systemic lupus erythematosus
    J H Anolik
    Department of Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA
    Lupus 22:342-9. 2013
    ....
  4. pmc Treatment targets in systemic lupus erythematosus: biology and clinical perspective
    Valentin Marian
    Department of Medicine, Division of Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, NY 14642, USA
    Arthritis Res Ther 14:S3. 2012
    ..The innate immune system activation then feeds back, driving autoreactive B-cell and T-cell survival and maturation. This self-perpetuating disease cycle creates the opportunity for targeted treatment inventions at multiple steps...
  5. pmc Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor
    James J Kobie
    Division of Allergy, Immunology and Rheumatology, University of Rochester Medical Center, 601 Elmwood Avenue, Box 695, Rochester, NY 14642, USA
    Arthritis Res Ther 13:R209. 2011
    ..Therefore, we asked if short-term effector (d5-d10) and memory (1 month or later) B cell responses to antigen were compromised in RA patients treated with anti-TNF therapy...
  6. ncbi request reprint New treatments for SLE: cell-depleting and anti-cytokine therapies
    Jennifer H Anolik
    Allergy, Immunology, Rheumatology Unit, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    Best Pract Res Clin Rheumatol 19:859-78. 2005
    ..Moreover, many additional cytokines, such as interleukin (IL)-6, IL-18, and the type I interferons, represent interesting future targets...
  7. ncbi request reprint B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny
    Jennifer H Anolik
    Department of Medicine, Division of Clinical Immunology and Rheumatology, James P Wilmot Cancer Center, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    Clin Immunol 122:139-45. 2007
    ..0001). Expansion of functionally immature B cells and decreased memory B cells may contribute to an immunodeficient state in patients recovering from rituximab mediated B cell depletion, particularly with repeated treatment...
  8. ncbi request reprint Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus
    Jennifer H Anolik
    University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Rochester, NY 14642, USA
    Arthritis Rheum 50:3580-90. 2004
    ....
  9. ncbi request reprint Down-regulation of CD20 on B cells upon CD40 activation
    Jennifer Anolik
    Department of Medicine, University of Rochester School of Medicine, Rochester 14642, USA
    Eur J Immunol 33:2398-409. 2003
    ....
  10. ncbi request reprint B cell depletion therapy in systemic lupus erythematosus
    Jennifer Anolik
    Department of Medicine Immunology and Rheumatology, University of Rochester School of Medicine, 601 Elmwood Avenue, Box 695, Rochester, NY 14642, USA
    Curr Rheumatol Rep 5:350-6. 2003
    ..Recent open-label studies indicate that rituximab is safe and may be efficacious in the treatment of SLE, and continued study with randomized clinical trials is justified...
  11. ncbi request reprint A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosus
    Chungwen Wei
    Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Rochester School of Medicine and Dentistry, NY 14642, USA
    J Immunol 178:6624-33. 2007
    ..These findings enhance our understanding of the B cell diversification pathways and provide mechanistic insight into the immunopathogenesis of SLE...
  12. ncbi request reprint New therapies for systemic lupus erythematosus: cellular targets
    R John Looney
    Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY14420, USA
    Rheum Dis Clin North Am 32:201-15, xi. 2006
    ..This article discusses the B-cell abnormalities found in systemic lupus erythematosus and the clinical and immunologic effects of anti-B-cell therapies...
  13. ncbi request reprint Treatment of SLE with anti-CD20 monoclonal antibody
    R John Looney
    Allergy Immunology, Rheumatology Unit, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    Curr Dir Autoimmun 8:193-205. 2005
    ..This article will review the role of B cells in human SLE as well as the currently available data on the treatment of SLE by depleting B cells with anti-CD20 (rituximab)...
  14. ncbi request reprint Profound hypogammaglobulinemia 7 years after treatment for indolent lymphoma
    Alison R Walker
    University of Rochester, Hematology Oncology, Rochester, New York 14642, USA alison
    Cancer Invest 26:431-3. 2008
    ..The patient was started on monthly intravenous immunoglobulin treatments with complete resolution of her symptoms...
  15. pmc Phenotypic and functional heterogeneity of human memory B cells
    Inaki Sanz
    Division of Allergy, Immunology and Rheumatology, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    Semin Immunol 20:67-82. 2008
    ....
  16. pmc A perspective on B-cell-targeting therapy for SLE
    R John Looney
    Division of Allergy Immunology Rheumatology, Department of Medicine, University of Rochester Medical Center, 601 Elmwood Ave, Room G 6427C, Rochester, NY, 14642, USA
    Mod Rheumatol 20:1-10. 2010
    ....
  17. pmc Reconstitution of the adult B cell repertoire after treatment with rituximab
    Inaki Sanz
    Division of Clinical Immunology and Rheumatology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
    Arthritis Res Ther 7:175-6. 2005
    ..The results presented by Rouzière and coworkers in their study of rheumatoid arthritis patients shed some light on this question and are discussed in this commentary...
  18. ncbi request reprint B cells as therapeutic targets for rheumatic diseases
    R John Looney
    Department of Medicine, University of Rochester, Box 695, 601 Elmwood Avenue, Rochester, NY 14642, USA
    Curr Opin Rheumatol 16:180-5. 2004
    ....
  19. ncbi request reprint Vaccine responses in patients with rheumatoid arthritis
    Rajan Ravikumar
    University of Rochester Medical Center, 601 Elmwood Avenue, Box 695, Rochester, NY 14642, USA
    Curr Rheumatol Rep 9:407-15. 2007
    ..Nevertheless, it is already clear that vaccination does induce response in many patients. Unfortunately, vaccination is underutilized in RA patients and needs to be aggressively promoted...
  20. ncbi request reprint B cells in human and murine systemic lupus erythematosus
    Jennifer Anolik
    Department of Medicine, Clinical Immunology and Rheumatology Unit, Rochester, New York 14642, USA
    Curr Opin Rheumatol 16:505-12. 2004
    ....
  21. pmc Human innate B cells: a link between host defense and autoimmunity?
    Eric C B Milner
    Department of Medicine, Clinical Immunology and Rheumatology Unit, University of Rochester Medical School, 601 Elmwood Avenue, Box 695, Rochester, NY 14642, USA
    Springer Semin Immunopathol 26:433-52. 2005
    ....
  22. doi request reprint Neuromyelitis optica spectrum disorder in a patient with systemic lupus erythematosus and anti-phospholipid antibody syndrome
    Lahar R Mehta
    Neuroimmunology Unit, Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642, USA
    Mult Scler 14:425-7. 2008
    ....
  23. ncbi request reprint Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy
    Jennifer H Anolik
    University of Rochester, Rochester, New York 14642, USA
    Arthritis Rheum 56:3044-56. 2007
    ..This study was undertaken to determine the magnitude, duration, and cause of these defects in rituximab-treated systemic lupus erythematosus (SLE) patients...
  24. ncbi request reprint B cell depletion therapy in autoimmune diseases
    Inaki Sanz
    Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
    Front Biosci 12:2546-67. 2007
    ..Finally, we will discuss some of the many challenges and opportunities that the medical and scientific community should address in the foreseeable future...
  25. ncbi request reprint B-cell-targeted therapy for systemic lupus erythematosus
    Ramin Sabahi
    University of Rochester School of Medicine, Rochester, New York 14642, USA
    Drugs 66:1933-48. 2006
    ....
  26. pmc Germinal center exclusion of autoreactive B cells is defective in human systemic lupus erythematosus
    Amedeo Cappione
    Department of Medicine, University of Rochester School of Medicine, Rochester, New York 14642, USA
    J Clin Invest 115:3205-16. 2005
    ..To our knowledge, this work represents the first comparative analysis of the fate of a specific autoreactive human B cell population. The results identify a defective tolerance checkpoint that appears to be specific for human SLE...
  27. ncbi request reprint B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab
    R John Looney
    University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
    Arthritis Rheum 50:2580-9. 2004
    ..B lymphocytes have been shown to play fundamental pathogenic roles in SLE, and therefore, elimination of B cells with the use of rituximab may represent a new therapy for SLE...
  28. ncbi request reprint Lupus IgG VH4.34 antibodies bind to a 220-kDa glycoform of CD45/B220 on the surface of human B lymphocytes
    Amedeo J Cappione
    Department of Medicine, Clinical Immunology and Rheumatology Unit, University of Rochester Medical Center, Rochester, NY 14642, USA
    J Immunol 172:4298-307. 2004
    ..Overall, our data indicate that V(H)4.34 Abs represent a major component of the lupus IgG autoantibody repertoire and suggest that the carbohydrate moiety they recognize may act as a selecting Ag in SLE...
  29. ncbi request reprint The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus
    Jennifer H Anolik
    University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
    Arthritis Rheum 48:455-9. 2003
    ....
  30. ncbi request reprint Targeted biologic approaches to the treatment of systemic vasculitis
    Andreea Coca
    University of Rochester School of Medicine, Rochester, NY 14642, USA
    Clin Rev Allergy Immunol 35:79-87. 2008
    ..Although most of these agents remain unproven until ongoing randomized clinical trials are complete, their introduction heralds a new era of vasculitis treatment and has provided novel insights into disease pathogenesis...

Research Grants4

  1. B-Cell Tolerance Mechanisms in Human SLE
    JENNIFER HOWITT ANOLIK; Fiscal Year: 2010
    ..The knowledge gained from the present studies will help us understand the multiple functions of B cells in autoimmunity and develop better strategies for the treatment of lupus and other autoimmune diseases. ..
  2. B-Cell Tolerance Mechanisms in Human SLE
    Jennifer Anolik; Fiscal Year: 2009
    ..The knowledge gained from the present studies will help us understand the multiple functions of B cells in autoimmunity and develop better strategies for the treatment of lupus and other autoimmune diseases. ..
  3. B cell functional and signaling abnormalities in SLE
    Jennifer Anolik; Fiscal Year: 2006
    ..abstract_text> ..
  4. B-Cell Tolerance Mechanisms in Human SLE
    Jennifer Anolik; Fiscal Year: 2009
    ..The knowledge gained from the present studies will help us understand the multiple functions of B cells in autoimmunity and develop better strategies for the treatment of lupus and other autoimmune diseases. ..